A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis - Related Studies

A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis

This study has been completed.

Study NCT00004816. Last updated on June 23, 2005. Information provided by Office of Rare Diseases (ORD)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Multiple Sclerosis

2	Additional conditions recognized in this trial
		Sclerosis

3	More general conditions related to this trial
		Autoimmune Diseases
		Autoimmune Diseases of the Nervous System
		Demyelinating Autoimmune Diseases, CNS
		Demyelinating Diseases
		Immune System Diseases
		Nervous System Diseases
		Pathologic Processes

4	Interventions listed in this trial
		monoclonal antibody M-T412

5	Additional drug interventions recognized in this trial
		Antibodies
		Antibodies, Monoclonal

6	More general drug interventions related to this trial
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

7	Sponsors listed in this trial
		National Center for Research Resources (NCRR)
		Stanford University